Disease · MONDO_0002974
Comparisons in its trials68
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 68
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab + CCRT vs Placebo + CCRT: deaths from any cause | 107 of 529 | 140 of 531 | 1,060 | NCT04221945 | Trial comparisons |
| Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab: Number of Participants Who Experience One or More Adverse Events (AEs) | 528 of 528 | 526 of 530 | 1,058 | NCT04221945 | Trial comparisons |
| Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab: Number of Participants Who Discontinue Study Treatment Due to an AE | 112 of 528 | 79 of 530 | 1,058 | NCT04221945 | Trial comparisons |
| Pembrolizumab + CCRT vs Placebo + CCRT: serious adverse events | 175 of 528 | 153 of 530 | 1,058 | NCT04221945 | Trial comparisons |
| Standard Chemoradiation vs Standard Chemoradiation With Adjuvant Chemotherapy: deaths from any cause | 123 of 456 | 109 of 463 | 919 | NCT01414608 | Trial comparisons |
| Standard Chemoradiation vs Standard Chemoradiation With Adjuvant Chemotherapy: serious adverse events | 98 of 453 | 107 of 361 | 814 | NCT01414608 | Trial comparisons |
| Durva + SoC CCRT vs Placebo + SoC CCRT: deaths from any cause | 91 of 385 | 112 of 385 | 770 | NCT03830866 | Trial comparisons |
| Durva + SoC CCRT vs Placebo + SoC CCRT: serious adverse events | 113 of 385 | 90 of 384 | 769 | NCT03830866 | Trial comparisons |
| Cemiplimab vs Investigator Choice (IC) Chemotherapy: Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1 | 52 of 304 | 19 of 304 | 608 | NCT03257267 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: deaths from any cause | 123 of 253 | 140 of 249 | 502 | NCT04697628 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 246 of 250 | 237 of 239 | 489 | NCT04697628 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: serious adverse events | 82 of 250 | 94 of 239 | 489 | NCT04697628 | Trial comparisons |
| Arm I (Cisplatin, IMRT or RT, Brachytherapy) vs Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine): deaths from any cause | 35 of 224 | 34 of 224 | 448 | NCT02466971 | Trial comparisons |
| Arm I (Cisplatin, IMRT or RT, Brachytherapy) vs Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine): serious adverse events | 45 of 208 | 45 of 202 | 410 | NCT02466971 | Trial comparisons |
| Concurrent Cisplatin and Radiation vs Concurrent Cisplatin, Tirapazamine and Radiation: serious adverse events | 42 of 190 | 65 of 180 | 370 | NCT00262821 | Trial comparisons |
| Arm I (Radiation) vs Arm II (Cisplatin + Radiation): serious adverse events | 7 of 170 | 9 of 161 | 331 | NCT01101451 | Trial comparisons |
| Arm I (Radiation) vs Arm II (Cisplatin + Radiation): deaths from any cause | 20 of 158 | 12 of 158 | 316 | NCT01101451 | Trial comparisons |
| Arm I: Cisplatin/Radiation Therapy vs Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel: deaths from any cause | 17 of 109 | 13 of 103 | 212 | NCT00980954 | Trial comparisons |
| Arm I: Cisplatin/Radiation Therapy vs Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel: serious adverse events | 14 of 107 | 25 of 101 | 208 | NCT00980954 | Trial comparisons |
| Standard Treatment (ST) vs Motivation + Problem Solving (MAPS): deaths from any cause | 4 of 100 | 4 of 102 | 202 | NCT02157610 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002974/comparisons